{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T22:04:27Z","timestamp":1743372267774},"reference-count":19,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.leukres.2012.06.012","type":"journal-article","created":{"date-parts":[[2012,7,12]],"date-time":"2012-07-12T19:20:41Z","timestamp":1342120841000},"page":"1311-1314","source":"Crossref","is-referenced-by-count":7,"title":["Nilotinib and imatinib inhibit cytarabine cellular uptake: Implications for combination therapy"],"prefix":"10.1016","volume":"36","author":[{"given":"Josy S.","family":"Naud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Ghani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro O.","family":"de Campos-Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2012.06.012_bib0005","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia","volume":"7","author":"Weisberg","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.leukres.2012.06.012_bib0010","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.06.012_bib0015","first-page":"2167","article-title":"Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate","volume":"8","author":"Kantarjian","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2012.06.012_bib0020","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias","volume":"100","author":"Ottmann","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.06.012_bib0025","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.06.012_bib0030","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.06.012_bib0035","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2012.06.012_bib0040","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.06.012_bib0045","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3324\/haematol.2009.016766","article-title":"Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia","volume":"95","author":"Deenik","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2012.06.012_bib0050","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/sj.leu.2402041","article-title":"Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells","volume":"15","author":"Topaly","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.06.012_bib0055","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood.V96.9.3195","article-title":"Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells","volume":"96","author":"Thiesing","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.06.012_bib0060","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00280-009-1158-7","article-title":"Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells","volume":"66","author":"Radujkovic","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2012.06.012_bib0065","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10555-007-9044-4","article-title":"The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs","volume":"26","author":"Zhang","year":"2007","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.leukres.2012.06.012_bib0070","doi-asserted-by":"crossref","first-page":"28364","DOI":"10.1074\/jbc.C200321200","article-title":"Inhibition of nucleoside transport by p38 MAPK inhibitors","volume":"277","author":"Huang","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2012.06.012_bib0075","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1124\/jpet.102.044214","article-title":"Inhibition of nucleoside transport by protein kinase inhibitors","volume":"304","author":"Huang","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.leukres.2012.06.012_bib0080","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00280-007-0629-y","article-title":"Imatinib inhibition of fludarabine uptake in T-lymphocytes","volume":"62","author":"Woodahl","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2012.06.012_bib0085","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2003-04-1010","article-title":"Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase","volume":"102","author":"Gardembas","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.06.012_bib0090","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V97.7.1999","article-title":"In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents","volume":"97","author":"Kano","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.06.012_bib0095","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/15257770802145892","article-title":"Imatinib-resistant CML cells have low ENT activity but maintain sensitivity to gemcitabine","volume":"27","author":"Leisewitz","year":"2008","journal-title":"Nucleosides Nucleotides Nucleic Acids"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612002792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612002792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T16:53:33Z","timestamp":1594400013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212612002792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0145212612002792"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2012.06.012","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}